InvestorsHub Logo
Post# of 252254
Next 10
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: urche post# 142745

Sunday, 05/27/2012 1:22:49 PM

Sunday, May 27, 2012 1:22:49 PM

Post# of 252254
Urche, when I wrote

the question raised by urche in #msg-75751678

I referred to this question:

However, I find it odd that the study apparently did not study the famous group of people with the Apo A-1 Milano variant who I thought clearly had a demonstrated profile with higher than normal HDL and lower than normal cardiovascular risk.

Regarding your other question on HDL subtypes, it is not a question addressed in the Lancet genetic study as they tested SNPs that are associated with elevated HDL-C plasma level and not a spesific HDL subtype. Their data implies that raising HDL-C plasma level alone is not going to be clinically useful. Perhaps targeting a specific subtype or changing HDL molecule from pro-inflammatory HDL to anti-inflammatory HDL instead of raising HDL-C is the way to go, but this is far beyond my knowledge.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.